{
  "retracted": false,
  "timestamp": 1535760000000,
  "updates": [
    {
      "timestamp": 1574857280261,
      "identifier": {
        "doi": "10.1016/j.ejca.2018.06.002"
      },
      "type": "erratum"
    }
  ],
  "identifier": {
    "doi": "10.1016/j.ejca.2017.05.001"
  },
  "journal": "European Journal of Cancer",
  "publisher": "Elsevier BV",
  "title": "Corrigendum to ‘Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study’ [Eur J Canc 81 (2017) 17–25]"
}
